Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026
Basics
Sector
Healthcare
Industry
Health Information Services
Country
United States
Market cap
14.0B USD
Enterprise value
14.7B USD
Full-time employees
3,800
Overall health
Strength:growing faster than most peersgrowing faster than peers
Drawback:less profitable than most peersless profitable than peers
Drawback:its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback:higher risk than most peers: its share price swings more than most peers’ (beta 3.72 vs a peer median of 0.63) and more debt relative to equity (3.25× vs a peer median of 0.22×)higher risk: bigger price swings (beta 3.72 vs peers 0.63) and more debt vs equity (3.25× vs peers 0.22×)
Ranks #967 of 1,157 healthcare companies (bottom 17%)
Paying shareholders without free cash flow. Paid out $11M over the 3 fiscal years to 2025 with -$699M of free cash flow.
Tempus AI returned $11M in buybacks and dividends over three fiscal years while its free cash flow totalled -$699M. The money came from its cash pile or from borrowing.
Much more borrowing than peers.Debt is 3.2× equity vs a peer median of 0.2×.Debt is 3.2× equity vs peers 0.2×.
Debt is 3.2× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 3.2× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.
Operating loss narrowing. Operating margin -20% in 2025, the smallest loss relative to revenue of the last 4 years.
Tempus AI still lost money on operations in 2025 (margin -20%), but that was its smallest operating loss relative to revenue in the 4 years of filings we have.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Tempus AI looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Sector-normalized EBITDA, earnings, and free cash flow yields.
Earnings yield-1.8%
SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148
EBITDA yield-1.3%
Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401
Free cash flow yield-1.9%
SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000
Revenue and earnings-per-share growth over one year, and revenue growth over three years.
Earnings per share growthUnavailable
The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991
3-year revenue growth58.3%
Yahoo Finance fallback · SEC figure unavailable or out of date · 3 fiscal years to Dec 2025Reported value33% base weight · Z-score 6.24Sector median: 0.0584 · MAD: 0.0840
Revenue growth50.4%
SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 4.55Sector median: 0.0609 · MAD: 0.0974
Yahoo Finance fallback · no standard SEC debt tagOutlier capped at sector 5th/95th percentile33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Tempus AI
Is Tempus AI getting weaker?
Its latest SEC filing (Jul 30, 2026) showed no major changes. Its overall score is unchanged at 31/100 since Oct 28, 2026.
How is Tempus AI valued vs its peers?
Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers.Earnings yield -1.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -1.8% vs peers 1.5% (weaker than 100% of peers).
Is Tempus AI growing?
Yes, faster than most of its peers. Growth scores 88/100 against 1,393 healthcare peers.3-year revenue growth 58.3% vs a peer median of 5.8% (stronger than 94% of peers).3-year revenue growth 58.3% vs peers 5.8% (stronger than 94% of peers).
How profitable is Tempus AI?
Less profitable than most of its peers. Profitability scores 25/100 against 1,393 healthcare peers.Return on invested capital -21.4% vs a peer median of 4.7% (weaker than 80% of peers).Return on invested capital -21.4% vs peers 4.7% (weaker than 80% of peers).
How risky is Tempus AI?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Beta 3.72 vs a peer median of 0.63 (weaker than 100% of peers).Beta 3.72 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Jul 30, 2026 · compared with the quarter ended Mar 31, 2026
No major changes
Previous quarter
Latest quarter
Change
Revenue (12 months)
1.4B USD
1.4B USD
+5.0%
Net income (12 months)
−302.9M USD
−254.4M USD
−16.0%
Operating margin
-19.7%
-19.8%
−0.1 pts
Free cash flow (12 months)
−212.9M USD
−263.2M USD
+23.6%
Cash
521.2M USD
599.6M USD
+15.1%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2022
FY 2023
FY 2024
FY 2025
Change
Operating margin
-82.8%
-36.9%
-99.7%
-19.9%
▲ 80 pts
Net margin
-90.4%
-40.3%
-101.8%
-19.3%
▲ 83 pts
Return on assets (ROA)
—
-38.0%
-76.2%
-10.8%
▲ 65 pts
Return on equity (ROE)
—
—
-1252.8%
-49.9%
▲ >999 pts
Free cash flow margin
-58.2%
-46.8%
-30.5%
-18.8%
▲ 12 pts
Current ratio
—
1.51×
2.29×
3.13×
▲ 37%
Quick ratio
—
1.38×
2.16×
3.00×
▲ 39%
Interest coverage
-12.12×
-4.18×
-12.88×
-3.60×
▲ 72%
TEM price history
Price history is added with the daily price update and will appear after the next one.